Mansi et al 2121 Mansi N, D'Agostino G, Scirè AS, Morpurgo G, Gregori D, Damiani V. A before-after assessment of the efficacy of Narivent(r) in the treatment of symptoms associated with allergic rhinitis in a pediatric population. Open Med Dev J 2012;4:80-86(2012) |
A before-after assessment of the efficacy of Narivent in the treatment of symptoms associated with allergic rhinitis in a pediatric population. |
20 patients of both genders, aged 5-18 years old, with persistent or intermittent allergic rhinitis. |
✓ |
✓ |
Damiani et al 1818 Damiani V, Camaioni A, Viti C, et al. Short-term Efficacy of Narivent(r) in the Treatment of Nasal Congestion. Open Med Dev J 2012;4:66-72(2012) |
Short-term efficacy of Narivent in the treatment of nasal congestion. |
36 patients (15 women and 21 men) with nasal congestion. Median age 42 years. |
✓ |
✓ |
Damiani et al 1919 Damiani V, Camaioni A, Viti C, Scirè AS, Morpurgo G, Gregori D. Long-term Efficacy of Narivent(r) in the Treatment of Nasal Congestion. Open Med Dev J 2012;4:73-79(2012) |
Long-term efficacy of Narivent in the treatment of nasal congestion. |
56 patients (28 women and 28 men) with persistent nasal congestion. Median age 48.5 years. |
✓ |
✓ |
Damiani et al 2020 Damiani V, Vicheva D, Camaioni A, et al. Economic Impact of Treatments for Controlling Symptoms Associatedwith Rhinitis: an Evaluation of Narivent(r) vs Standard Therapy. The Open Med Dev J 2012;4:61-65(2012) |
Economic impact of treatments for controlling symptoms associated with rhinitis: an evaluation of Narivent vs standard therapy. |
Literature review: 6680 papers in the past 5 years. Data extraction & probability density reconstruction. Monte Carlo sampling. |
✓ |
✓ |
Damiani et al 2222 Damiani V, Camaioni A, Viti C, Scirè AS, Morpurgo G, Gregori D. A single-centre, before-after study of the short- and long-term efficacy of Narivent((r)) in the treatment of nasal congestion. J Int Med Res 2012;40(5):1931-1941(2012) |
A single-center, before-after study of the short- and long-term efficacy of Narivent in the treatment of nasal congestion. |
92 patients with persistent nasal congestion divided in two groups: Group 1 consisting of 36 patients (7-day treatment) and Group 2 consisting of 56 patients (30-day treatment). |
✓ |
✓ |
Cuppari et al 2323 Cuppari C, Salpietro A, Grasso L, et al. HMGB1 and allergic rhinitis in children: preliminary results after corticosteroids or glycyrrhetic acid intranasal treatment. The Child 2012;1; (2):1-2(2012) |
HMGB1 and allergic rhinitis in children: preliminary results after corticosteroids or glycyrrhetic acid intranasal treatment. |
59 patients evaluated. 35 children (19 boys and 16 girls, median age 9.3 ± 3.7 years) with allergic rhinitis and monosensitized to Parietaria, were evaluated. The control group consisted of 24 healthy children (11 boys and 13 girls, median age 9.1 ± 4.1 years). |
✓ |
✓ |
Passali et al 1515 Passali D, Kern E, Lei Chen R, Bellussi L. High mobility group box 1 (HMGB 1): a new protein in the pathogenesis of ENT inflammatory and infectious diseases. Acta Otorhinolaryngol Ital 2012;32(1):46-47(2012) |
High mobility group box 1 (HMGB1): a new protein in the pathogenesis of ENT inflammatory and infectious disease. |
Preliminary data about the role of HMGB1 protein in ENT inflammatory and infectious. |
✓ |
– |
Bellussi et al 1616 Bellussi LM, Chen L, Chen D, Passali FM, Passali D. The role of High Mobility Group Box 1 chromosomal protein in the pathogenesis of chronic sinusitis and nasal polyposis. Acta Otorhinolaryngol Ital 2012;32(6):386-392(2012) |
The role of high mobility group box 1 chromosomal protein in the pathogenesis of chronic sinusitis and nasal Polyps. |
Nasal polyps tissue from 21 patients with CRSwNP including 1 patient with asthma and 2 patients with allergic rhinitis and 8 healthy control subjects were collected. |
✓ |
– |
Salpietro et al 1717 Salpietro C, Cuppari C, Grasso L, et al. Nasal high-mobility group box-1 protein in children with allergic rhinitis. Int Arch Allergy Immunol 2013;161(2):116-121(2013) |
Nasal High-Mobility Group Box-1 Protein in Children with Allergic Rhinitis. |
104 allergic rhinitis subjects (48 males and 56 females, median age 10.3 ± 3.4 years) and 97 healthy children (42 males and 55 females, median age 9.8 ± 4.1 years). |
✓ |
– |
Hong et al 2525 Hong SM, Cho JS, Um JY, et al. Increased expression of highmobility group protein B1 in chronic rhinosinusitis. Am J Rhinol Allergy 2013;27(4):278-282(2013) |
Increased expression of high-mobility group protein B1 in chronic rhinosinusitis. |
Paranasal sinus mucosa was obtained from 10 patients with CRS and 10 patients without CRS. |
✓ |
– |
Bellussi et al 2626 Bellussi LM, Iosif C, Sarafoleanu C, et al. Are HMGB1 protein expression and secretion markers of upper airways inflammatory diseases? J Biol Regul Homeost Agents 2013;27(3):791-804(2013) |
Are HMGB1 protein expression and secretion markers of upper airways inflammatory diseases? |
10 biopsies of nasal mucosa from patients with CRS without NP and 31 CRS with NP were randomly selected. As controls were included 3 biopsies of normal nasal mucosa that were harvested from healthy patients with no symptoms or nasal allergies. (Mean age = 47.35 years) |
✓ |
– |
Chen et al 2727 Chen D, Bellussi LM, Passali D, Chen L. LPS may enhance expression and release of HMGB1 in human nasal epithelial cells in vitro. Acta Otorhinolaryngol Ital 2013;33(6):398-404(2013) |
LPS may enhance expression and release of HMGB1 in human nasal epithelial cells in vitro. |
Nasal polyps and paranasal sinus mucosa from 10 patients requiring surgery for their sinusitis |
✓ |
– |
Ullah et al 2828 UllahMA, Loh Z, Gan WJ, et al. Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammation. J Allergy Clin Immunol 2014;134(2):440-450(2014) |
Receptor for advanced glycation end products and its ligand high-mobility group box 1 mediate allergic airway sensitization and airway inflammation. |
TLR4(−/ − ), RAGE(−/ − ), and RAGE-TLR4(−/ − ) mice received intranasal exposure to Dermatophagoides pteronyssinus or Blatella germanica extracts, and researchers measured features of allergic inflammation during the sensitization or challenge phase. They used anti-HMGB1 antibody and the IL-1 receptor antagonist Anakinra to inhibit HMGB1 and the IL-1 receptor, respectively. |
✓ |
– |
Mansi et al 2424 Mansi N, D'Agostino G, Scirè AS, et al. Allergic Rhinitis in Children: A Randomized Clinical Trial Targeted at Symptoms. Indian J Otolaryngol Head Neck Surg 2014;66(4):386-393(2014) |
Allergic Rhinitis in Children: A Randomized Clinical Trial Targeted at Symptoms. |
40 patients, aged between 5 and 18 years old, were randomly divided into two groups (20 cases and 20 controls) and followed for 30 days. |
✓ |
✓ |
Chen et al 2929 Chen D, Mao M, Bellussi LM, Passali D, Chen L. Increase of high mobility group box chromosomal protein 1 in eosinophilic chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol 2014; 4(6):453-462(2014) |
Increase of high mobility group box chromosomal protein 1 in eosinophilic chronic rhinosinusitis with nasal polyps. |
Researchers collected nasal polyps specimens from 41 patients with CRSwNP (20 eosinophilic and 21 noneosinophilic) undergoing functional endoscopic sinus surgery (FESS). Biopsies of uncinate process, and ethmoidal mucosa from 9 non-CRS patients were used as controls. |
✓ |
– |
Paris et al 3030 Paris G, Pozharskaya T, Asempa T, Lane AP. Damage-associated molecular patterns stimulate interleukin-33 expression in nasal polyp epithelial cells. Int Forum Allergy Rhinol 2014;4(1):15-21(2014) |
Damage-associated molecular patterns stimulate interleukin 33 expression in nasal polyp epithelial cells. |
Ethmoid tissue was obtained from 8 recalcitrant CRSwNP and 9 control subjects during endoscopic sinus surgery (ESS). |
✓ |
– |
Musumeci et al 3131 Musumeci D, Roviello GN, Montesarchio D. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1- related pathologies. Pharmacol Ther 2014;141(3):347-357(2014) |
An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. |
Review describes various approaches recently proposed in the literature to inhibit HMGB1 and the related inflammatory processes, especially focusing on the block of RAGE–HMGB1 signaling. |
✓ |
✓ |
Min et al 3232 Min HJ, Kim SJ, Kim TH, Chung HJ, Yoon JH, Kim CH. Level of secreted HMGB1 correlates with severity of inflammation in chronic rhinosinusitis. Laryngoscope 2015;125(7):E225-E230(2015) |
Level of secreted HMGB1 correlates with severity of inflammation in chronic rhinosinusitis. |
Total 63 nasal lavage fluid samples were collected from 38 patients (16–76 years old) with chronic rhinosinusitis who underwent endoscopic sinus surgery. |
✓ |
– |
Cavone et al 3333 Cavone L, Cuppari C, Manti S, et al. Increase in the level of proinflammatory cytokine HMGB1 in nasal fluids of patients with rhinitis and its sequestration by glycyrrhizin induces eosinophils cell death. Clin Exp Otorhinolaryngol 2015;8(2): 123-128(2015) |
Increase in the Level of Proinflammatory Cytokine HMGB1 in Nasal Fluids of Patients with Rhinitis and its Sequestration by Glycyrrhizin Induces Eosinophil Cell Death. |
170 Allergic Rhinitis subjects (87 males and 83 females; median age, 10.3 ± 3.4 years). 1 puff of saline (29 males and 28 females), one group received 1 puff of Budesonide (32 males and 25 females) and one group received 1 puff of Narivent (DMG, Rome, Italy) (30 males and 26 females) into each nostril 2 times a day for 1 week. |
✓ |
✓ |
Dzaman et al 3434 Dzaman K, SzczepanskiMJ, Molinska-GluraM, Krzeski A, Zagor M. Expression of the receptor for advanced glycation end products, a target for high mobility group box 1 protein, and its role in chronic recalcitrant rhinosinusitis with nasal polyps. Arch Immunol Ther Exp (Warsz) 2015;63(3):223-230(2015) |
Expression of the receptor for advanced glycation end products, a target for high mobility group box 1 protein, and its role in recalcitrant rhinosinusitis with nasal polyps. |
25 patients with recalcitrant CRSwNPs are included in the study (13 males and 12 females. Median age: 47 years; range 24–77 years). |
✓ |
– |
Dzaman et al 3535 Dzaman K, Zagor M, Molinska-Glura M, Krzeski A. High motility group box 1 (HMGB1) protein and its receptor for advanced glycation end products (RAGE) expression in chronic rhinosinusitis without nasal polyps. Folia Histochem Cytobiol 2015;53(1):70-78(2015) |
High motility group box 1 (HMGB1) protein and its receptor for advanced glycation end products (RAGE) expression in chronic rhinosinusitis without nasal polyps. |
37 patients with CRS without nasal polyps (19 males and 18 females; median age 42 years, range 15–71 years) and 26 normal controls (18 males and 8 females. Median age 40 years; range 16–69 years) were enrolled in this study. |
✓ |
– |